Compare IFS & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IFS | RYTM |
|---|---|---|
| Founded | 1897 | 2008 |
| Country | Peru | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.8B |
| IPO Year | 2014 | 2017 |
| Metric | IFS | RYTM |
|---|---|---|
| Price | $57.79 | $96.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 14 |
| Target Price | $48.00 | ★ $131.14 |
| AVG Volume (30 Days) | 373.1K | ★ 555.5K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.85% | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $55.34 |
| Revenue Next Year | $7.38 | $86.06 |
| P/E Ratio | $9.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.39 | $60.99 |
| 52 Week High | $57.10 | $122.20 |
| Indicator | IFS | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 70.08 | 63.16 |
| Support Level | $43.65 | $82.43 |
| Resistance Level | N/A | $100.69 |
| Average True Range (ATR) | 1.96 | 4.45 |
| MACD | 0.76 | 0.65 |
| Stochastic Oscillator | 99.36 | 83.20 |
Intercorp Financial Services Inc is a provider of banking, insurance, wealth management services, and payments for retail customers and commercial clients in Peru. Its purpose is centered around building financial well-being together. The company has three operating business segments: Banking, mainly loans, credit facilities, deposits, and current accounts; Insurance provides life annuity products with single-premium payment and conventional life insurance products, as well as other retail insurance products; and Wealth management provides brokerage and investment management services. Inteligo serves mainly Peruvian citizens.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.